OCGN Announces 31% Lesion Growth Reduction in Phase 2 GA Trial, 55% ≥30% Shrinkage, No SAEs, Phase 3 Ready
Ocugen, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.37
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS